Ignite Creation Date:
2024-05-05 @ 4:49 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00327223
Status:
COMPLETED
Last Update Posted:
2008-03-14
First Post:
2006-05-17
Brief Title:
Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy
Sponsor:
AmpliMed Corporation
Organization:
AmpliMed Corporation
Study Overview
Official Title:
A Phase 1 Trial of Amplimexon Imexon Inj Administered Daily for 5 Days Every 3 Weeks to Patients With Metastatic Cancer or Disseminated Malignancy
Status:
COMPLETED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
AMP-011 is a Phase 1 study designed to extend the understanding of the toxicity and pharmacology of imexon by investigating a schedule of daily treatment for 5 days every three weeks The objective of the study is to determine the maximally tolerated dose the pharmacokinetics and the toxicity of the drug on the designated schedule
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None